Protagonist Therapeutics (PTGX) Other financing activities (2016 - 2026)

Protagonist Therapeutics (PTGX) has 11 years of Other financing activities data on file, last reported at $23.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities rose 96.06% year-over-year to $23.4 million; the trailing twelve-month figure through Mar 2026 stood at $34.8 million (up 13.8% YoY), and the FY2025 full-year result was $23.3 million, down 11.76% from the prior year.
• Other financing activities advanced to $23.4 million in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $23.4 million in Q1 2026 to a low of -$3.7 million in Q4 2023.
• A 5-year average of $4.6 million and a median of $2.6 million in 2024 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities sank 768.35% in 2023 and soared 1080.31% in 2024, its largest moves.
• Tracing PTGX's Other financing activities over 5 years: stood at $553000.0 in 2022, then sank by 768.35% to -$3.7 million in 2023, then surged by 209.06% to $4.0 million in 2024, then declined by 29.62% to $2.8 million in 2025, then surged by 723.9% to $23.4 million in 2026.
• Business Quant data shows PTGX's Other financing activities at $23.4 million in Q1 2026, $2.8 million in Q4 2025, and $5.7 million in Q3 2025.